In the AML cohort, mutated signal transduction genes were mutually exclusive, with the exception of one patient who presented variants in BRAF and NRAS. In MDS, only 11% (3/27) of patients had mutated genes in this functional group. Here, BRAF is linked to myelodysplastic syndrome.